Moderna is developing mRNA vaccines for endemic human coronavirus
- Will CAR-NK Cancer Therapy Surpass High-Cost CAR-T Immunotherapy?
- What is the role of Platelet Dynamics in Cancer Progression?
- Biomarkers can detect rapid aging of organs and disease risks
- Avoiding “Off-Target” Effects: Researchers Enhance the Safety of Future mRNA Therapies
- Japan: Sales Halted for ‘Cannabis Gummies’ as Health Issues Mount
- Evaluation of the carcinogenicity of organic fluorine compounds raised by WHO subsidiary
Moderna is developing mRNA vaccines for endemic human coronavirus
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Moderna is developing mRNA vaccines for endemic human coronavirus.
On March 25, Moderna announced at its third annual Vaccine Day that it is preparing to develop a vaccine candidate (mRNA-1287) against the endemic human coronavirus (HCoV).
It targets four coronaviruses: HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
These 4 coronaviruses are not unpredictable and destructive in human impact and usually only cause common colds and upper respiratory tract infections.
But for some high-risk groups (such as the elderly), viral infections can also lead to further severe illness, such as secondary bacterial infections and pneumonia.
Globally, 10%-30% of upper respiratory tract infections are caused by the above four viruses, which are the second most common cause of common cold after rhinovirus.
“It would be a good idea to develop this vaccine if it could induce protection in high-risk individuals, especially against seasonal respiratory viruses,” said former FDA acting chief scientist Luciana Borio.
Moderna didn’t share many details about its mRNA-1287 vaccine candidate and didn’t respond to a request for comment, but the vaccine will likely be administered intramuscularly like other vaccines.
However, data from the mRNA Covid-19 vaccine show that intramuscular injection does not provide the durable protection against coronavirus infection and symptomatic disease that is hoped for in a common cold vaccine.
Moderna is developing mRNA vaccines for endemic human coronavirus
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
